Related Experiment Video
Updated: Jun 7, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Prevalence of mild cognitive impairment and its subtypes in the Heinz Nixdorf Recall study cohort
Martha Dlugaj1, Christian Weimar, Natalia Wege
1Department of Neurology, University Hospital Essen, Essen, Germany. Martha.Dlugaj@uk-essen.de
Aims:
We investigated the prevalence of mild cognitive impairment (MCI) and its subtypes according to the original (MCI-original) and modified (MCI-modified; neglecting cognitive complaints) Petersen criteria.
Methods:
4,145 subjects (aged 50-80 years) from a German population-based study completed a cognitive screening test and were poststratified into 2 groups with sample sizes of 1,125 for impaired and 3,020 for age-appropriate performance. Random samples of 445 impaired participants and 211 age-appropriate participants received a detailed neuropsychological evaluation. The prevalence of MCI was estimated by a bias correction estimator based on stratum weights. The association between MCI and age, gender and education was analyzed in a logistic regression model.
Results:
The estimated MCI prevalence was 7.8% (95% CI: 5.7-9.9%) for the original, and 12.1% (95% CI: 9.8-14.4%) for the modified criteria. In the MCI-original group, amnestic MCI subtypes were slightly less common than non-amnestic MCI subtypes (3.5 vs. 4.3%). MCI-original was associated with lower education and older age. In the MCI-modified group, the amnestic subtypes were more common than the non-amnestic MCI subtypes (7.8 vs. 4.3%), and MCI was associated with age, gender and education.
Conclusions:
Prevalence rates of MCI are high in the general population and vary considerably according to the criteria applied.
Insights
Prevalence of mild cognitive impairment (MCI) is high in older adults, with modified criteria identifying more cases. Subtype prevalence and associated factors like age and education differ based on the criteria used.
Area of Science:
- Gerontology and Cognitive Neurology
- Epidemiology of Neurodegenerative Diseases
Background:
- Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia.
- Accurate prevalence estimation of MCI is crucial for understanding population health and planning interventions.
Purpose of the Study:
- To investigate the prevalence of mild cognitive impairment (MCI) using both original and modified Petersen criteria.
- To compare the subtypes of MCI and their associations with demographic factors under different diagnostic criteria.
Main Methods:
- A German population-based study included 4,145 subjects aged 50-80 years.
- Cognitive screening was followed by detailed neuropsychological evaluation in selected participants.
- Prevalence was estimated using bias correction, and logistic regression analyzed associations with age, gender, and education.
Main Results:
- MCI prevalence was 7.8% with original criteria and 12.1% with modified criteria.
- Amnestic MCI subtypes were more prevalent under modified criteria (7.8% vs. 4.3%).
- MCI prevalence was associated with older age, lower education, and gender, varying by criteria.
Conclusions:
- Prevalence rates of MCI are substantial in the general population.
- The choice of diagnostic criteria significantly impacts MCI prevalence and subtype distribution.
- Understanding these variations is key for accurate epidemiological assessment and clinical management.
More Related Videos
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
Related Concept Videos
Dementia l: Introduction
Alzheimer Disease l: Introduction
Dementia
The progression of dementia is generally gradual.
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive Development During Adulthood